Activating mutations in KRAS and BRAF are found in more than 30% of all human tumours and 40% of melanoma, respectively, thus targeting this pathway could have broad therapeutic effects 1 . Small molecule ATP-competitive RAF kinase inhibitors have potent antitumour effects on mutant BRAF(V600E) tumours but, in contrast to mitogen-activated protein kinase kinase (MEK) inhibitors, are not potent against RAS mutant tumour models, despite RAF functioning as a key effector downstream of RAS and upstream of MEK 2,3 . Here we show that ATP-competitive RAF inhibitors have two opposing mechanisms of action depending on the cellular context. In BRAF(V600E) tumours, RAF inhibitors effectively block the mitogen-activated protein kinase (MAPK) signalling pathway and decrease tumour growth. Notably, in KRAS mutant and RAS/RAF wild-type tumours, RAF inhibitors activate the RAF-MEK-ERK pathway in a RAS-dependent manner, thus enhancing tumour growth in some xenograft models. Inhibitor binding activates wild-type RAF isoforms by inducing dimerization, membrane localization and interaction with RAS-GTP. These events occur independently of kinase inhibition and are, instead, linked to direct conformational effects of inhibitors on the RAF kinase domain. On the basis of these findings, we demonstrate that ATP-competitive kinase inhibitors can have opposing functions as inhibitors or activators of signalling pathways, depending on the cellular context. Furthermore, this work provides new insights into the therapeutic use of ATP-competitive RAF inhibitors.
. Immunohistochemistry of serial skin sections showed increased staining for the proliferation marker Ki67 in the keratinocyte compartment of sections from inhibitor-but not vehicle-treated animals, co-localized with increased cytoplasmic phospho-ERK staining (Fig. 1c) , which is intriguing in light of the recent clinical reports of 1 Genentech, South San Francisco, California 94080, USA. 2 Array BioPharma, Boulder, Colorado 80301, USA. cutaneous squamous cell carcinoma and keratoacanthoma for two selective RAF inhibitors [7] [8] [9] . RAF inhibitor treatment of tumour cell lines in vitro resulted in the induction of phospho-MEK and phospho-ERK levels in the RAS/RAF-WT (MeWo) and KRAS-MT (H2122) lines, versus their sustained inhibition in BRAF(V600E) (A375) cells (Fig. 2a) . Knockdown of CRAF (also known as RAF1), but not BRAF, in HCT116 (KRAS-MT) cells 10 was able to reverse the phospho-MEK induction observed after RAF inhibitor treatment, indicating that CRAF has the major role in signalling to MEK (Fig. 2b) . Notably, both BRAF and CRAF kinase activities increased in a dose-dependent manner after GDC-0879 treatment, selectively in non-BRAF(V600E) lines (Fig. 2c) . The PLX4720 RAF inhibitor showed more modest effects, inducing moderate CRAF activity at a high concentration. Activation of ARAF was also observed selectively after GDC-0879 treatment, and dual ARAF and CRAF knockdown was synergistic in decreasing inhibitorinduced phospho-MEK levels in HCT116 (KRAS-MT) cells (Supplementary Fig. 5 ).
RAF activation proceeds through the formation of homo-and heterodimers [11] [12] [13] . The RAF inhibitor GDC-0879 induced B-C and A-B heterodimers together with the induction of A-, B-and CRAF kinase activities ( Fig. 2c and Supplementary Figs 5 and 6 ). Because RAF heterodimers are expected to have higher specific kinase activity 12 and low activity BRAF mutants can cause CRAF activation through heterodimerization 11, 14 , we tested whether BRAF is required for CRAF activation and MEK phosphorylation. Treatment of isogenic BRAF 1/1 and BRAF 2/2 cell lines 15, 16 with RAF inhibitors resulted in a similar induction of CRAF specific activity as well as phospho-MEK and phospho-ERK levels, demonstrating that BRAF is not essential (Supplementary Figs 7 and 8) . Notably, in addition to heterodimers, RAF inhibitors induced CRAF homodimers ( Supplementary Fig. 7c ), providing a further mechanism for priming of CRAF activity 17 when other isoforms are not expressed or heterodimer formation is impaired, as is the case for PLX4720 treatment. Kinase activation of CRAF(T421N), a gatekeeper mutant that does not bind either GDC-0879 or PLX4720, was markedly impaired and phospho-MEK induction after RAF inhibitor treatment in CRAF(T421N) transfectants was similar to untransfected controls, demonstrating that inhibitor binding to the CRAF nucleotide-binding pocket is required for effective CRAF activation and downstream signalling (Fig. 2d , e and Supplementary Fig. 9b, c) .
To address the question of whether CRAF kinase activity was required for phospho-MEK induction by RAF inhibitors, we characterized the chemically unrelated ATP-competitive RAF inhibitor AZ-628 (ref. 18) , which binds to the inactive conformation of the RAF kinase active site motif Asp-Phe-Gly (DFG-out conformation), has high potency against CRAF and a very slow/irreversible off-rate ( Supplementary Figs 10 and 12 Fig. 10 ). This series of experiments suggests that CRAF kinase activity is required for both phospho-MEK induction and cellular hyper-proliferation.
To gain a better understanding of the RAF activation sequence in response to inhibitor priming, we characterized the topology of the events and the role of RAS-GTP. Fractionation experiments demonstrated that all RAF inhibitors tested, except PLX4720, induced a dose-dependent translocation to the membrane fraction of BRAF and CRAF, accompanied by increased CRAF(S338) phosphorylation 19 , selectively in non-BRAF(V600E) lines ( Fig. 3a and Supplementary Fig. 11 ). Membrane targeting was RAS-GTP dependent, because expression of dominant-negative KRAS(S17N) led to cytoplasmic retention of CRAF after inhibitor treatment, versus the membrane localization observed with KRAS-WT (Fig. 3b) . RAF inhibitors induce membrane and/or cytosolic phospho-MEK levels, together with their effects on CRAF localization, with the exception of AZ-628 as previously discussed ( Fig. 3a and Supplementary Figs 10 and 11). After KRAS(S17N) transfection, the induction of both membrane and cytosolic phospho-MEK levels is significantly impaired (Supplementary Fig. 11b) . Thus, as a consequence of inhibitor binding, CRAF gets activated in a RAS-GTP-dependent manner, through membrane translocation, Ser 338 phosphorylation and dimerization [20] [21] [22] . The important role of RAS-GTP is further underscored by the fact that transfection of BRAF(V600E) A375 cells with activated mutant KRAS(G12D), but not wild-type KRAS, leads to CRAF-BRAF heterodimerization and CRAF kinase activation after inhibitor treatment ( Supplementary Fig. 11d ).
The conformation of the ATP-binding pocket is crucial for kinase maturation and has an important role in the ability of small molecules to prime and induce the translocation of their target kinases to the membrane [23] [24] [25] . Membrane targeting of CRAF requires inhibitor binding to the ATP-binding pocket, because the gatekeeper threonine mutant CRAF(T421N) (which does not bind to GDC-0879 and weakly to AZ-628; Supplementary Fig. 9a ) remains in the cytoplasm after inhibitor treatment (Fig. 3c) . Furthermore, membrane targeting of CRAF does not seem to require kinase activity, as CRAF(D486A), a DFG-loop aspartate mutant devoid of kinase activity, is still able to translocate to the membrane (Fig. 3c) as long as it can bind the inhibitor, as is the case for AZ-628 but not GDC-0879 ( Supplementary  Fig. 12a ). Thus, membrane targeting is not due to CRAF kinase inhibition and does not proceed through an extrinsic mechanism, such as feedback, but instead relies on inhibitor occupancy of the ATP-binding pocket.
To test further whether priming was mediated by the inhibitors' conformational effects on the RAF kinase domain, we assayed BRAF-CRAF heterodimerization biochemically. The CRAF kinase domain forms a stable complex with the BRAF kinase domain in the absence of any inhibitor in an immunoprecipitation and western blot assay using purified recombinant proteins (Fig. 4a) . Notably, both a non-hydrolysable analogue of ATP and PLX4720 destabilize, whereas AZ-628 and GDC-0879 significantly stabilize, the CRAF-BRAF heterodimer kinase domain interaction (Fig. 4a) . This result is consistent with our findings from the cellular immunoprecipitation and western blot experiments in non-BRAF(V600E) cell lines (Supplementary Figs 6 and 10) , and supports the model that dimerization is mediated directly through the inhibitors' effects on the RAF kinase domain, rather than being a secondary effect. The inhibitors had no effect on the basal interaction between the CRAF and BRAF(V600E) kinase domains (Fig. 4a) , in agreement with the cellular data demonstrating lack of priming in BRAF(V600E) mutant lines ( Fig. 2 and Supplementary Fig. 6 ). In summary, our biochemical and cellular data suggests that inhibitor occupancy of the ATP-binding pocket can effect RAF dimerization and that the inhibitors' effects are different from ATP itself.
To probe further the structural basis of the inhibitors' effects on CRAF we solved the crystal structure of the CRAF kinase domain complexed to a close analogue of GDC-0879 (ref. 4) (Supplementary Fig. 13 and Supplementary Table 1 ). The CRAF-inhibitor complex adopts a dimer conformation in the asymmetric unit, as previously described for BRAF 26 . Comparison of the CRAF and BRAF homodimers shows an extremely well-conserved interface, the single difference among them residing in the most amino-terminal residue of CRAF resolved in the crystal structure, CRAF(Y340), within its negative-charged regulatory region 27 ( Fig. 4b and Supplementary Table 2 ). Further amino acid residues that differ between BRAF and CRAF are highlighted in Fig. 4b . A heterodimer model of BRAF-CRAF illustrates that, in contrast to the conformation induced by GDC-0879 and AZ-628 when bound to BRAF, PLX4720 induces a shift in the aC-helix in BRAF (cyan), bringing it closer to the dimer interface, which may affect priming (Fig. 4c) .
Finally, to demonstrate formally that modulation of kinase domain dimerization by ATP-competitive RAF inhibitors underlies their ability to activate CRAF and downstream signalling to MEK, we generated CRAF and BRAF dimer interface mutants that either constitutively heterodimerize (CRAF(E478K) and BRAF(E586K)) or are defective in dimerization (CRAF(R401H) and BRAF(R509H)) 26 . Cotransfection of CRAF(E478K) and BRAF(E586K) in HCT116 KRAS-MT cells resulted in a basal increase of exogenous CRAF kinase activity compared to wild-type controls (Fig. 4d) . No further induction was observed after RAF inhibitor treatment, confirming that dimerization is the main driver for the inhibitors' effects on CRAF kinase activity. Constitutive heterodimerization by these mutants was confirmed (Fig. 4d) , suggesting that the interactions characterized by our assays were mediated at the level of kinase domain dimer interface. In contrast, co-transfection of CRAF(R401H) and BRAF(R509H) lead to decreased levels of basal CRAF activity and a significant impairment of CRAF activation by RAF inhibitors, consistent with the mutants' defective heterodimerization properties (Fig. 4d) . Phospho-MEK level induction by RAF inhibitors correlated with the efficiency of heterodimer formation and CRAF activation in all cases (Supplementary Fig. 15 ).
In conclusion, we have discovered that ATP-competitive RAF inhibitors have opposing roles as inhibitors and activators of the RAF-MEK-ERK pathway, and that the outcome is dependent on cellular context and genotype. In BRAF(V600E) cells, the pathway is sensitized to ATP-competitive RAF inhibitors owing to the higher ATP apparent K m (K m(app) ) of the mutant BRAF(V600E) protein (Supplementary Fig. 4 ) and lack of CRAF activation ( Supplementary Fig. 1 ). In BRAF-WT cells, inhibitors trigger the CRAF activation sequence, which can lead to MEK/ERK phosphorylation and in some cases to enhanced growth (Supplementary Fig. 1 ). This suggests that careful assessment should be made of the functional consequences of other ATP-competitive inhibitors with respect to priming, which may affect the inhibitors' efficacy and safety profiles. On the basis of our findings, we propose that preventing activation of CRAF could potentially prevent undesirable effects of RAF inhibitors on normal tissue and non-BRAF(V600E) tumours. This could be attained by an allosteric non-ATP competitive mechanism that would prevent RAF dimerization, or RAS-RAF RAS-binding domain (RBD) interaction. This data also highlights the need for BRAF(V600E) patient selection in V600E-selective RAF inhibitor clinical trials.
METHODS SUMMARY
Chemicals and cell culture. PLX4720 and PD0325901 were purchased from Symansis, and EMD from CalBiochem. AZ-628 was synthesized according to the procedure described in patent number WO2006024834 (http://www.wipo. int/pctdb/en/wo.jsp?wo52006024834). Fluorescence microscopy. For CRAF sub-cellular localization experiments, HEK293T cells were transiently transfected with relevant cyan fluorescent protein (CFP)-KRAS and Venus-CRAF constructs and TagBFP or mCherry-H2B to identify nuclei. Compounds were added 20 h after transfection and live cells were imaged 24 h after transfection. Tumour xenograft studies and immunohistochemistry. Tumour fragments were obtained from MEXF514, LXFA983 and LXFA1041 xenografts. In vivo studies were conducted at Oncotest. Immunohistochemistry were conducted as described previously 3 . In vitro kinase assays. Cell lysates were immunoprecipitated with anti-CRAF, anti-BRAF or anti-GFP antibody (Millipore) and then incubated with 0.4 mg unactive MEK1 (Millipore) in 40 ml of kinase buffer (20 mM MOPS, pH 7.2, 25 mM b-glycerol phosphate, 5 mM EGTA, 1 mM sodium orthovanadate, 1 mM dithiothreitol (DTT), 120 mM ATP, 18 mM MgCl 2 ) for 30 min at 30 uC. Samples were then loaded onto the Meso Scale Discovery Phospho (Ser 217/ 221)/Total MEK1/2 assay plates and quantified. Expression and crystallization of CRAF. The dual expression baculovirus construct pBac4x-1-HTH-CRAF(324-618):CDC37 was expressed in Hi5 cells. CRAF was co-crystallized with inhibitor in hanging drops (12% PEG 8K, 100 mM Tris, pH 8.0, 10% tacsimate, grown at 12 uC). RAF dimerization. His-BRAF-WT kinase domain or His-BRAF(V600E) kinase domain and glutathione S-transferase (GST)-CRAF kinase domain (Invitrogen) were incubated in the presence of a fixed concentration of compound or dimethylsulphoxide (DMSO) for 1 h and immunoprecipitated with a rabbit anti-GST antibody. 
